HB 1780

  • Illinois House Bill
  • 102nd Regular Session
  • Introduced in House Mar 31, 2022
  • Passed House Feb 23, 2022
  • Passed Senate Mar 31, 2022
  • Signed by Governor Jun 10, 2022

Drug Take-Back Act

Abstract

Provides that the Act may be cited as the Drug Take-Back Act. Requires covered manufacturers to, no later than July 1, 2022 or 6 months after becoming a covered manufacturer, whichever is later, participate in an approved drug take-back program or have established and implemented a drug take-back program independently or as part of a group of covered manufacturers. Provides requirements for the drug take-back program and for manufacturer program operators. Requires each manufacturer program operator to submit a proposal for the establishment and implementation of a drug take-back program to the Environmental Protection Agency for review and approval. Contains provisions regarding changes or modifications to drug take-back programs, promotion of drug take-back programs, annual reports, funding, and reimbursement. Requires covered manufacturers and manufacturer program operators to submit an annual $5,000 registration fee. Provides civil penalties. Contains other provisions. Amends the Freedom of Information Act. Provides that proprietary information submitted to the Environmental Protection Agency under the Pharmaceutical Recovery Act is exempt from inspection and copying under the Act. Preempts home rule. Contains other provisions. Effective immediately. House Committee Amendment No. 1 Adds reference to: 415 ILCS 5/22.15 from Ch. 111 1/2, par. 1022.15 415 ILCS 5/22.55 Replaces everything after the enacting clause with the provisions of the introduced bill with the following changes. Provides that each covered manufacturer must, beginning January 1, 2024 (rather than no later than July 1, 2022) or 6 months after becoming a covered manufacturer, individually or collectively implement (rather than participate in) an approved drug take-back program. Requires a drug take-back program to provide for the collection, transportation, and disposal of covered drugs. Provides that specified requirements shall be undertaken by a drug take-back program or a covered manufacturer (rather than a manufacturer program operator). Requires the Agency to review all proposals in conjunction with one another to ensure the proposals are coordinated to achieve authorized collection site coverage. Requires the Agency to either approve, reject, or approve with modification a proposal within 90 days after receiving it. Requires drug take-back program promotion to be implemented by all drug take-back programs collectively. Provides that a manufacturer program operator shall (rather than may) allocate administration and operation costs of programs to participating covered manufacturers. Requires each covered manufacturer and manufacturer program operator to register with the Agency and submit the registration fee by January 1, 2023 (rather than April 1, 2022), and by January 1 (rather than April 1) of each year thereafter. Removes language requiring penalties collected under the Act to be used in accordance with the Act's provisions. Removes language allowing the Agency to impose a civil penalty for a violation of the Act of $7,000 per violation per day. Makes other changes. Amends the Environmental Protection Act. Provides that moneys in the Solid Waste Management Fund shall be used solely for the administration of the Act (rather than for the administration of the Consumer Electronics Recycling Act and, until January 1, 2020, the Electronic Products Recycling and Reuse Act). Removes provisions requiring the Agency to (1) develop and implement a public information program regarding household waste drop-off points that accept pharmaceutical products, as well as mail-back programs; (2) develop a sign that provides information on the proper disposal of unused pharmaceutical products; and (3) establish, by rule, a statewide medication take-back program by June 1, 2016 to ensure that there are pharmaceutical product disposal options regularly available for residents across the State. Makes other changes. Effective immediately. House Floor Amendment No. 2 Provides that "covered drug" means, among other things, a drug. Makes a typographical change. Senate Committee Amendment No. 1 In provisions of the Drug Take-Back Act, makes the following changes. Provides that "covered drug" does not include drugs sold at retail as a unit dose package or homeopathic drugs. Makes changes to the definition of "proprietary information". Provides that program promotion requirements do not apply to any drug take-back program established prior to the Act's effective date that provides promotional or educational materials to the public about the proper collection and management of covered drugs. Provides that each covered manufacturer and covered manufacturer program operator shall submit a registration fee of $2,500 (rather than $5,000). Senate Committee Amendment No. 2 Removes language providing that the definition of "covered manufacturer" does not include a pharmacy. Provides that private label distributors and repackagers are not covered manufacturers. Senate Floor Amendment No. 3 Requires the Environmental Protection Agency to provide a 30-day public comment period on drug take-back program proposals and revised proposals during specified 90-day periods. Provides that the reason for the Agency's rejection of a drug take-back program proposal must be provided in the written notification to the manufacturer program operator.

Bill Sponsors (26)

Votes


Actions


Jun 10, 2022

House

Governor Approved

House

Public Act . . . . . . . . . 102-1055

House

Effective Date June 10, 2022

May 12, 2022

House

Sent to the Governor

Apr 22, 2022

Senate

Added as Alternate Co-Sponsor Sen. Jacqueline Y. Collins

Apr 13, 2022

House

Motion to Reconsider Vote - Withdrawn Rep. Daniel Didech

House

Passed Both Houses

Apr 07, 2022

House

Senate Committee Amendment No. 2 House Concurs 095-014-000

House

Motion Filed to Reconsider Vote Rep. Daniel Didech

House

House Concurs

House

Senate Floor Amendment No. 3 House Concurs 095-014-000

House

Senate Committee Amendment No. 1 House Concurs 095-014-000

Apr 06, 2022

House

Senate Committee Amendment No. 2 Motion to Concur Recommends Be Adopted Rules Committee; 003-001-000

House

Senate Floor Amendment No. 3 Motion to Concur Recommends Be Adopted Rules Committee; 003-001-000

House

Senate Committee Amendment No. 1 Motion to Concur Recommends Be Adopted Rules Committee; 003-001-000

Apr 01, 2022

House

Senate Committee Amendment No. 2 Motion Filed Concur Rep. Jennifer Gong-Gershowitz

House

Senate Floor Amendment No. 3 Motion to Concur Referred to Rules Committee

House

Senate Committee Amendment No. 2 Motion to Concur Referred to Rules Committee

House

Senate Committee Amendment No. 1 Motion to Concur Referred to Rules Committee

House

Senate Floor Amendment No. 3 Motion Filed Concur Rep. Jennifer Gong-Gershowitz

House

Senate Committee Amendment No. 1 Motion Filed Concur Rep. Jennifer Gong-Gershowitz

Mar 31, 2022

Senate

Recalled to Second Reading

House

Placed on Calendar Order of Concurrence Senate Amendment(s) 1, 2, 3

House

Arrived in House

Senate

Third Reading - Passed; 046-002-000

Senate

Placed on Calendar Order of 3rd Reading

Senate

Senate Floor Amendment No. 3 Adopted; Fine

Senate

Added as Alternate Co-Sponsor Sen. Laura Ellman

Senate

Added as Alternate Chief Co-Sponsor Sen. Patricia Van Pelt

Senate

Added as Alternate Chief Co-Sponsor Sen. Sara Feigenholtz

Senate

Added as Alternate Co-Sponsor Sen. Ann Gillespie

Mar 30, 2022

Senate

Senate Floor Amendment No. 3 Recommend Do Adopt Executive; 015-000-000

Mar 28, 2022

Senate

Senate Floor Amendment No. 3 Assignments Refers to Executive

Mar 25, 2022

Senate

Senate Floor Amendment No. 3 Referred to Assignments

Senate

Senate Floor Amendment No. 3 Filed with Secretary by Sen. Laura Fine

Mar 23, 2022

Senate

Do Pass as Amended Executive; 016-000-000

Senate

Senate Committee Amendment No. 1 Adopted

Senate

Senate Committee Amendment No. 2 Adopted

Senate

Placed on Calendar Order of 3rd Reading March 24, 2022

Senate

Second Reading

Senate

Placed on Calendar Order of 2nd Reading

Mar 22, 2022

Senate

Senate Committee Amendment No. 1 Assignments Refers to Executive

Senate

Senate Committee Amendment No. 2 Assignments Refers to Executive

Mar 18, 2022

Senate

Senate Committee Amendment No. 2 Filed with Secretary by Sen. Laura Fine

Senate

Senate Committee Amendment No. 2 Referred to Assignments

Mar 16, 2022

Senate

Senate Committee Amendment No. 1 Referred to Assignments

Senate

Senate Committee Amendment No. 1 Filed with Secretary by Sen. Laura Fine

Mar 02, 2022

Senate

Assigned to Executive

Feb 23, 2022

Senate

Referred to Assignments

Senate

First Reading

Senate

Added as Alternate Chief Co-Sponsor Sen. Antonio Muñoz

Senate

Chief Senate Sponsor Sen. Laura Fine

Senate

Placed on Calendar Order of First Reading

House

Third Reading - Short Debate - Passed 096-013-000

Senate

Arrive in Senate

Feb 22, 2022

House

Second Reading - Short Debate

House

Placed on Calendar Order of 3rd Reading - Short Debate

House

House Floor Amendment No. 2 Adopted

Feb 17, 2022

House

House Floor Amendment No. 2 Recommends Be Adopted Rules Committee; 004-000-000

Feb 16, 2022

House

House Floor Amendment No. 2 Referred to Rules Committee

House

House Floor Amendment No. 2 Filed with Clerk by Rep. Jennifer Gong-Gershowitz

Feb 15, 2022

House

Added Co-Sponsor Rep. Jaime M. Andrade, Jr.

House

Placed on Calendar 2nd Reading - Short Debate

Feb 10, 2022

House

Added Co-Sponsor Rep. Mark Luft

House

Added Co-Sponsor Rep. Joyce Mason

Feb 09, 2022

House

Do Pass as Amended / Short Debate Prescription Drug Affordability & Accessibility Committee; 015-002-000

House

Added Co-Sponsor Rep. Martin McLaughlin

House

House Committee Amendment No. 1 Adopted in Prescription Drug Affordability & Accessibility Committee; by Voice Vote

Feb 08, 2022

House

House Committee Amendment No. 1 Rules Refers to Prescription Drug Affordability & Accessibility Committee

Feb 07, 2022

House

Added Co-Sponsor Rep. Lawrence Walsh, Jr.

House

Added Co-Sponsor Rep. Anthony DeLuca

Feb 03, 2022

House

Added Co-Sponsor Rep. Ann M. Williams

Feb 02, 2022

House

Added Co-Sponsor Rep. Robyn Gabel

Feb 01, 2022

House

Added Co-Sponsor Rep. Ryan Spain

Jan 31, 2022

House

House Committee Amendment No. 1 Filed with Clerk by Rep. Jennifer Gong-Gershowitz

House

House Committee Amendment No. 1 Referred to Rules Committee

Jan 27, 2022

House

Added Co-Sponsor Rep. Robert Rita

Jan 26, 2022

House

Added Chief Co-Sponsor Rep. Tom Demmer

Jan 11, 2022

House

Assigned to Prescription Drug Affordability & Accessibility Committee

Mar 27, 2021

House

Rule 19(a) / Re-referred to Rules Committee

Mar 26, 2021

House

Added Chief Co-Sponsor Rep. Dagmara Avelar

House

Added Co-Sponsor Rep. Michelle Mussman

Mar 11, 2021

House

Added Co-Sponsor Rep. Kambium Buckner

Mar 09, 2021

House

Added Co-Sponsor Rep. Deb Conroy

House

Assigned to Prescription Drug Affordability & Accessibility Committee

Mar 01, 2021

House

Added Co-Sponsor Rep. Kelly M. Cassidy

Feb 26, 2021

House

Added Co-Sponsor Rep. Anne Stava-Murray

Feb 24, 2021

House

Added Co-Sponsor Rep. Terra Costa Howard

Feb 17, 2021

House

First Reading

House

Referred to Rules Committee

Feb 16, 2021

House

Filed with the Clerk by Rep. Jennifer Gong-Gershowitz

Bill Text

Bill Text Versions Format
Introduced HTML PDF
Engrossed HTML PDF
Enrolled HTML PDF
House Amendment 001 HTML PDF
House Amendment 002 HTML PDF
Senate Amendment 001 HTML PDF
Senate Amendment 002 HTML PDF
Senate Amendment 003 HTML PDF

Related Documents

Document Format
Public Act

Sources

Data on Open States is updated periodically throughout the day from the official website of the Illinois General Assembly.

If you notice any inconsistencies with these official sources, feel free to file an issue.